Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07514260
PHASE1

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.

Official title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-295 in Healthy Japanese Subjects With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-03-31

Completion Date

2027-01

Last Updated

2026-04-07

Healthy Volunteers

Yes

Interventions

DRUG

ABBV-295

Subcutaneous Injections

DRUG

Placebo for ABBV-295

Subcutaneous Injections

Locations (1)

CenExel ACT- Anaheim Clinical Trials /ID# 280879

Anaheim, California, United States